Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma [Yahoo! Finance]
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Bluecrux & Pharmaceutical Innovator Forge Path Toward QC & Supply Chain Integration: "Revolutionizing Lab Operations for Enhanced Efficiency"
Legend Biotech Co. (NASDAQ: LEGN) was upgraded by analysts at Scotiabank from a "sector perform" rating to a "sector outperform" rating. They now have a $65.00 price target on the stock.